Limits...
The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cells.

Kim MH, Joo HG - J. Vet. Sci. (2009)

Bottom Line: Taxol has been used effectively in cancer therapies.An inhibition assay using N-p-tosyl-(L)-phenylalanine chloromethyl ketone confirmed that NF-kappaB was intimately involved in the effects of taxol on DC viability.Taken together, these results confirm that taxol increases DC viability, and this information may provide new insights for new clinical applications of both taxol and DCs.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University, Jeju, Korea.

ABSTRACT
Taxol has been used effectively in cancer therapies. Our previous study demonstrated that taxol induced altered maturation and improved viability of dendritic cells (DCs). However, the effects of taxol on DC viability have not been fully elucidated. In the present study, flow cytometric analyses revealed that taxol treatment significantly increased the number of viable DCs and the expression levels of a representative anti-apoptotic protein Bcl-xL. Furthermore, mobilization of the p65 subunit of nuclear factor-kappaB (NF-kappaB) from the cytosol to the nucleus in DCs was observed by confocal microscopy. An inhibition assay using N-p-tosyl-(L)-phenylalanine chloromethyl ketone confirmed that NF-kappaB was intimately involved in the effects of taxol on DC viability. In addition, we investigated the mechanisms of taxol enhancement of DC viability. Since taxol is a popular anticancer agent used in clinic, this study may provide a rationale for the use of taxol in DC immunotherapy to treat cancer patients. Taken together, these results confirm that taxol increases DC viability, and this information may provide new insights for new clinical applications of both taxol and DCs.

Show MeSH

Related in: MedlinePlus

Bcl-xL expression in dendritic cells increased after taxol treatment. Representative data from three independent experiments are presented (A). The optical density of each band was divided by that of the β-actin band, and the ratio at 0 h was set at 100% (B).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2801113&req=5

Figure 3: Bcl-xL expression in dendritic cells increased after taxol treatment. Representative data from three independent experiments are presented (A). The optical density of each band was divided by that of the β-actin band, and the ratio at 0 h was set at 100% (B).

Mentions: Western blot analysis showed that Bcl-xL expression in TaxolDCs was increased after 6 h of treatment, whereas the expression levels of Bcl-2 and Bax were not increased (Fig. 3). The protein expression levels were calculated in comparison to the level of β-actin (internal control). The results suggest that taxol enhances DC viability via the increase of the anti-apoptotic protein Bcl-xL as a potential mechanism of action.


The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cells.

Kim MH, Joo HG - J. Vet. Sci. (2009)

Bcl-xL expression in dendritic cells increased after taxol treatment. Representative data from three independent experiments are presented (A). The optical density of each band was divided by that of the β-actin band, and the ratio at 0 h was set at 100% (B).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2801113&req=5

Figure 3: Bcl-xL expression in dendritic cells increased after taxol treatment. Representative data from three independent experiments are presented (A). The optical density of each band was divided by that of the β-actin band, and the ratio at 0 h was set at 100% (B).
Mentions: Western blot analysis showed that Bcl-xL expression in TaxolDCs was increased after 6 h of treatment, whereas the expression levels of Bcl-2 and Bax were not increased (Fig. 3). The protein expression levels were calculated in comparison to the level of β-actin (internal control). The results suggest that taxol enhances DC viability via the increase of the anti-apoptotic protein Bcl-xL as a potential mechanism of action.

Bottom Line: Taxol has been used effectively in cancer therapies.An inhibition assay using N-p-tosyl-(L)-phenylalanine chloromethyl ketone confirmed that NF-kappaB was intimately involved in the effects of taxol on DC viability.Taken together, these results confirm that taxol increases DC viability, and this information may provide new insights for new clinical applications of both taxol and DCs.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University, Jeju, Korea.

ABSTRACT
Taxol has been used effectively in cancer therapies. Our previous study demonstrated that taxol induced altered maturation and improved viability of dendritic cells (DCs). However, the effects of taxol on DC viability have not been fully elucidated. In the present study, flow cytometric analyses revealed that taxol treatment significantly increased the number of viable DCs and the expression levels of a representative anti-apoptotic protein Bcl-xL. Furthermore, mobilization of the p65 subunit of nuclear factor-kappaB (NF-kappaB) from the cytosol to the nucleus in DCs was observed by confocal microscopy. An inhibition assay using N-p-tosyl-(L)-phenylalanine chloromethyl ketone confirmed that NF-kappaB was intimately involved in the effects of taxol on DC viability. In addition, we investigated the mechanisms of taxol enhancement of DC viability. Since taxol is a popular anticancer agent used in clinic, this study may provide a rationale for the use of taxol in DC immunotherapy to treat cancer patients. Taken together, these results confirm that taxol increases DC viability, and this information may provide new insights for new clinical applications of both taxol and DCs.

Show MeSH
Related in: MedlinePlus